caa a22 4500 469074418 CHVBK 20180323132931.0 cr unu---uuuuu 170328e19920901xx s 000 0 eng 10.1007/BF01741549 doi (NATIONALLICENCE)springer-10.1007/BF01741549 The human repertoire of antibody specificities against Thomsen-Friedenreich and Tn-carcinoma-associated antigens as defined by human monoclonal antibodies [Elektronische Daten] [Bo Jansson, Carl Borrebaeck] Summary: Human monoclonal antibodies specific for tumour-associated Thomsen-Friedenreich (TF) [Gal(β1-3)GalNAc(α)-O-] and Tn [GalNAc(α)-O-] glycoproteins were prepared using peripheral blood lymphocytes from healthy blood donors. The B lymphocytes were either directly transformed with Epstein-Barr virus (EBV) or transformed after an in vitro stimulation period with synthetic glycoproteins. The EBV-transformed lymphocytes were subsequently fused with a mouse-human heteromyeloma to secure antibody production and stability. IgM antibodies exhibiting different patterns of specificity for synthetic TF and Tn antigens were obtained, including antibodies specific for the α and β forms of different Gal(β1-3)GalNAc-O- and GalNAc-O- conjugates and antibodies agglutinating neuraminidase-treated erythrocytes. Several of the human monoclonal antibodies showed an increased binding to cultured carcinoma cells as compared to melanoma cells. This straightforward approach for the production of human monoclonal antibodies demonstrates the possibility of investigating the reactivity pattern of tumour-binding antibodies from peripheral blood lymphocytes. The binding patterns of these monoclonal antibodies show that healthy donors carry different fine specificities against synthetic TF/Tn antigens and that these antibodies react with different tumour cells. Springer-Verlag, 1992 In vitro immunization nationallicence Human monoclonal antibody nationallicence Thomsen-Friedenrich antigen nationallicence Tn antigen nationallicence T antigen nationallicence Jansson Bo BioInvent International AB, S-223 70, Lund, Sweden aut Borrebaeck Carl Department of Immunotechnology, Lund University, P. O. Box 7031, S-220 07, Lund, Sweden aut Cancer Immunology, Immunotherapy Springer-Verlag 34/5(1992-09-01), 294-298 0340-7004 34:5<294 1992 34 262 https://doi.org/10.1007/BF01741549 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01741549 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Jansson Bo BioInvent International AB, S-223 70, Lund, Sweden aut NATIONALLICENCE 700 1- Borrebaeck Carl Department of Immunotechnology, Lund University, P. O. Box 7031, S-220 07, Lund, Sweden aut NATIONALLICENCE 773 0- Cancer Immunology, Immunotherapy Springer-Verlag 34/5(1992-09-01), 294-298 0340-7004 34:5<294 1992 34 262 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer